The influence of age on the disposition of theophylline was studied in 95 adult patients (nonsmokers) with bronchial asthma requiring oral theophylline therapy: 17 patients age ≥39 years, 50 patients age 40–59 years, and 28 patients < 60 years. A decrease was observed in total body clearance together with an increase in the elimination half-life of theophylline parallel to the advance in age of the patients. The apparent volume of distribution of theophylline was similar in the three groups of patients. According to the results obtained, recommendations are made regarding the dosage regimens of theophylline in elderly patients.
EllisEFKoysookoRLevyG, Pharmacokinetics of theophylline in children with asthma. Pediatrics1976; 58: 542–7.
2.
LoughnanPMSitarDSOgilvieRIEisenAFoxZNeimsAH, Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. J Pediatr1976; 88: 874–9.
BauerLRBlouinRA, Influence of age on theophylline clearance in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet1981; 6: 469–74.
9.
KoupJRSchentagJJVanceJWKuritzkyPMPyszczynskiDRJuskoWJ, System for clinical pharmacokinetic monitoring of theophylline therapy. Am J Hosp Pharm1976; 33: 949–56.
HoraiYIshizakiTSasakiTWatanabeMKabeJ, Individualized aminophylline therapy in patients with obstructive airway disease: Oral dosage prediction from an intravenous test dose. Eur J Clin Pharmacol1982; 23: 111–21.
12.
OteroMJ, Eficacia del control de niveles sericos de teofilina en pacientes con asma bronquial cronica (thesis). Salamanca, Spain: University of Salamanca, 1984.
13.
DvorchikBHVesellES, Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clin Pharmacol Ther1978; 23: 617–23.
14.
SheinerBJ, ELSFIT: Program for extended least squares fit to individual pharmacokinetic data. San Francisco: Division Clinical Pharmacology, University of California, 1981.
15.
SlatteryJT, A pharmacokinetic model-independent approach for estimating dose required to give desired steady-state trough concentrations of drug in plasma. J Pharmacokinet Biopharm1980; 8: 105–10.
16.
JacksonShdWrightJM, Sustained serum theophylline concentrations during chronic twice-daily administration of a slow release preparation. Eur J Clin Pharmacol1983; 24: 205–8.
17.
PiafskyKMOgilvieRI, Dosage of theophylline in bronchial asthma. N Engl J Med1975; 292: 1218–22.
18.
HendelesLWeinbergerMWyattR, Guide to oral theophylline therapy for the treatment of chronic asthma. Am J Dis Child1978; 132: 876–80.
19.
MarlinGEButcherMAKlumppJAThompsonPJ, Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease. Br J Clin Pharmacol1980; 10: 265–71.
20.
CabanasRPenaJCastro-GagoMTojoR.Individualization of dosage for oral theophylline therapy. J Pediatr1982; 100: 169–70.
